NCT07427446 Dexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium
| NCT ID | NCT07427446 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Kasr El Aini Hospital |
| Condition | Emergence Delirium |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 50 participants in total. It began in 2026-02-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Fifty children undergoing heart catheterization without local anesthesia in the skin will be randomly divided into two groups. Group DM (Dexmedetomidine + Midazolam) and Group KM (Ketamine + Midazolam)
Eligibility Criteria
Inclusion Criteria: * Scheduled for elective cardiac catheterization under general anesthesia. Exclusion Criteria: * neurological disorder, psychiatric disease, or current psychoactive medication. * allergy. * significant systemic comorbidities.
Contact & Investigator
Ahmed Elhaddad, Ass.prof.
PRINCIPAL INVESTIGATOR
Faculty of medicins,Cairo university
Frequently Asked Questions
Who can join the NCT07427446 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 6 Years, studying Emergence Delirium. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07427446 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07427446 currently recruiting?
Yes, NCT07427446 is actively recruiting participants. Contact the research team at drblacksmith@gmail.com for enrollment information.
Where is the NCT07427446 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07427446 clinical trial?
NCT07427446 is sponsored by Kasr El Aini Hospital. The principal investigator is Ahmed Elhaddad, Ass.prof. at Faculty of medicins,Cairo university. The trial plans to enroll 50 participants.